Johnson & Johnson T-Cell Therapy Shows Promising Initial Results in Lymphoma Study

By Kelly Cloonan

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, or LBCL.

The company said Friday the data show a 75% to 80% complete response rate among evaluable patients with relapsed or refractory LBCL who received the recommended Phase 2 dose.

The findings demonstrate the therapy's potential in treating such patients, including those with diffuse large B-cell lymphoma, which is the most common type of aggressive lymphoma, the company said.

The therapy also showed a promising safety profile, with no cases of Grade 3 or 4 cytokine-release syndrome observed in the cohort receiving the recommended Phase 2 dose, the company said.

Two patients had immune effector cell-associated neurotoxicity syndrome, including one Grade 3 event, which occurred in a patient with central nervous system lymphoma, the company said.

Overall, 84% of patients had Grade 3 or 4 treatment-emergent adverse events. The most common was neutropenia, a reduction in white blood cells, the company said.

The therapy is designed to bind to both CD19 and CD20 antigens, two cell surface proteins commonly expressed on malignant B-cells, in order to potentially address common resistance mechanisms in relapsed or refractory disease, the company said.

Write to Kelly Cloonan at [e-mail]

(END) Dow Jones Newswires

06-13-25 1158ET